# OnCo record bryet (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/bryet/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "bryet" ;
  schema:name "BrYet"@en ;
  schema:alternateName "BrYet US, Inc."@en ;
  schema:description "BrYet is developing ML-016, a form of the chemotherapy drug doxorubicin packed into tiny silicon particles meant to deliver it to cancer that has spread to the lungs or liver. It began an early trial in Australia in 2026."@en ;
  schema:url <https://onco.cc/companies/bryet/>, <https://bryetpharma.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://bryetpharma.com/>, <https://bryetpharma.com/technology/>, <https://bryetpharma.com/news/>, <https://clinicaltrials.gov/study/NCT07723482> ;
  schema:addressCountry "US" ;
  onco:sections <https://onco.cc/fronts/chemotherapy/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:trials <https://onco.cc/trials/nct07723482/> .